Halozyme Therapeutics Inc Cash Flow Quality Index
Halozyme Therapeutics Inc cash flow quality index. Halozyme Therapeutics Inc (HALO) has a Cash Flow Quality Index of 1.02x as of September 2025. Operating cash flow of $178.60 Million exceeds net income of $175.22 Million, indicating high earnings quality where cash backs reported profits. See Halozyme Therapeutics Inc (HALO) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Halozyme Therapeutics Inc (2017–2024)
Cash flow quality index of Halozyme Therapeutics Inc from 2017 to 2024. Historical Cash Flow Quality Index for Halozyme Therapeutics Inc across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore HALO debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Halozyme Therapeutics Inc Cash Flow Quality Index by Year (2017–2024)
Halozyme Therapeutics Inc cash flow quality index by year from 2017 to 2024. Year-by-year earnings quality comparison for Halozyme Therapeutics Inc. For the full cash flow conversion analysis, see Halozyme Therapeutics Inc cash conversion from operations.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.08x | $479.06 Million | $444.09 Million | ▼ -21.8% |
| 2023 | 1.38x | $388.57 Million | $281.59 Million | ▲ +16.2% |
| 2022 | 1.19x | $240.11 Million | $202.13 Million | ▲ +59.8% |
| 2021 | 0.74x | $299.44 Million | $402.71 Million | ▲ +73.1% |
| 2020 | 0.43x | $55.45 Million | $129.09 Million | ▼ -79.8% |
| 2017 | 2.13x | $134.05 Million | $62.97 Million | — |